目的 探討復(fù)方川芎膠囊聯(lián)合鹽酸阿羅洛爾片治療心絞痛的臨床療效。方法 選擇2020年6月-2021年6月在濮陽市油田總醫(yī)院治療的118例心絞痛患者,根據(jù)用藥的差別分為對照組和治療組,每組各59例。對照組口服鹽酸阿羅洛爾片,10 mg/次,1次/d;治療組在對照組基礎(chǔ)上口服復(fù)方川芎膠囊,4粒/次,3次/d。兩組均經(jīng)8周治療。觀察兩組患者臨床療效,比較治療前后兩組患者心絞痛發(fā)作次數(shù)和持續(xù)時間,SAQ、GQOLI-74和Duke評分,及血清血管性血友病因子(vWF)、人正五聚蛋白3(PTX3)、血管細(xì)胞黏附分子1(VCAM1)、血管內(nèi)皮生長因子(VEGF)和轉(zhuǎn)化生長因子β結(jié)合蛋白2(LTBP2)水平。結(jié)果 經(jīng)治療,治療組總有效率明顯高于對照組(98.31% vs 86.44%,P<0.05)。治療后,兩組患者心絞痛發(fā)作次數(shù)、持續(xù)時間均減少(P<0.05),且治療組比對照組減少更明顯(P<0.05)。經(jīng)治療,兩組患者SAQ評分、GQOLI-74評分、Duke評分均明顯升高(P<0.05),且治療組明顯高于對照組(P<0.05)。治療后,兩組vWF、PTX-3、VCAM-1、LTBP-2水平明顯降低,而VEGF水平升高(P<0.05),且治療組血清學(xué)指標(biāo)改善優(yōu)于對照組(P<0.05)。結(jié)論 復(fù)方川芎膠囊聯(lián)合鹽酸阿羅洛爾片治療心絞痛,不僅促進癥狀改善,還能夠促進機體細(xì)胞因子和生活質(zhì)量的改善,具有一定臨床推廣應(yīng)用價值。

Objective To explore the clinical efficacy of Compound Chuanxiong Capsules combined with arotinolol hydrochloride in treatment of angina pectoris. Methods Patients (118 cases) with angina pectoris in Puyang Oilfield General Hospital from June 2020 to June 2021 were divided into control and treatment group based on different treatments, and each group had 59 cases. Patients in the control group were po administered with Arotinolol Hydrochloride Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Compound Chuanxiong Capsules on the basis of the control group, 6 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluation was evaluated, the frequency and duration of angina pectoris, scores of SAQ, GQOLI-74, and Duke, the levels of serological indexes vWF, PTX-3, VCAM-1, VEGF, and LTBP-2 in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (98.31% vs 86.44%, P < 0.05). After treatment, the attack times and duration of angina pectoris were significantly decreased in two groups (P < 0.05), and the times and duration of angina pectoris in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the scores of SAQ, GQOLI-74 and Duke in two groups were significantly increased (P < 0.05), and which in the treatment group were significantly higher than those in the control group (P < 0.05). After treatment, the levels of vWF, PTX-3, VCAM-1 and LTBP-2 in both groups were significantly decreased, while the level of VEGF was increased (P < 0.05), and the improvement of serological indexes in the treatment group was better than that in the control group (P < 0.05). Conclusion Compound Chuanxiong Capsules combined with arotinolol hydrochloride in treatment of angina pectoris can not only promote the improvement of symptoms, but also promote the improvement of cytokines and quality of life, which has a certain clinical application value.

R972

河南省醫(yī)學(xué)科技攻關(guān)項目（2014070510）